Quarterly ResultMay 6, 2026, 04:09 PM
Insulet Q1 Revenue +33.9% to $761.7M; EPS $1.30
AI Summary
Insulet Corp reported strong first-quarter 2026 results with total revenue increasing by 33.9% to $761.7 million and diluted EPS rising by 160% to $1.30. The company expanded its share repurchase program by an additional $350 million and repurchased $300 million of common stock. Insulet also launched Omnipod 5 in five Middle East countries and advanced development of its next-generation AID product, Omnipod 6, including enrolling the first participant in the EVOLVE pivotal study for type 2 diabetes.
Key Highlights
- Total revenue increased 33.9% to $761.7 million for Q1 2026.
- Net income surged 157.3% to $91.1 million for the quarter.
- Diluted earnings per share rose 160% to $1.30.
- Board approved an additional $350 million for share repurchases, completing $300 million in Q1 2026.
- U.S. Omnipod product revenue grew 28.3% to $515.6 million.
- International Omnipod product revenue increased 59.4% to $242.9 million.
- Net cash provided by operating activities was $113.8 million, up from $63.8 million.
- Accrued $11.7 million for a voluntary medical device correction for Omnipod 5 Pods.
Price Impact
More from PODD